Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection

被引:12
作者
Chi, Chen-Ta [1 ,2 ]
Lee, I-Cheng [1 ]
Lee, Rheun-Chuan [3 ]
Hung, Ya-Wen [1 ]
Su, Chien-Wei [1 ]
Hou, Ming-Chih [1 ]
Chao, Yee [4 ]
Huang, Yi-Hsiang [1 ,2 ]
机构
[1] Taipei Vet Gen Hosp, Dept Med, Div Gastroenterol & Hepatol, Taipei 11217, Taiwan
[2] Natl Yang Ming Chiao Tung Univ, Sch Med, Inst Clin Med, Taipei 11221, Taiwan
[3] Taipei Vet Gen Hosp, Dept Radiol, Taipei 11217, Taiwan
[4] Taipei Vet Gen Hosp, Dept Oncol, Taipei 11217, Taiwan
关键词
hepatocellular carcinoma; HBV; transarterial chemoembolization; tumor burden; ALBI-grade migration; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; B-VIRUS REACTIVATION; LIPIODOL CHEMOEMBOLIZATION; HEPATIC-FAILURE; LIVER-FUNCTION; RISK-FACTORS; SUBCLASSIFICATION; CANCER; THERAPY; MODEL;
D O I
10.3390/cancers13174325
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary BCLC-B HCC encompasses heterogeneous populations with varied tumor burden and liver reserve resulting in diverse clinical outcomes to TACE. Liver function deterioration would happen after TACE in patients with high tumor burden. Here, we found that the risk of post-TACE acute ALBI-grade migration was 24.3% and chronic ALBI-grade migration was 16% for BCLC-B HCC patients; HBV infection, up-to-seven criteria, and up-to-eleven criteria were factors of acute ALBI-grade migration, whereas bilobar tumor involvement had high risk of chronic ALBI migration once acute ALBI-grade migration developed after TACE. Overall, up-to-eleven criteria consistently associated with acute and chronic ALBI-grade migration, suggesting that up-to-eleven is an appropriate parameter to select TACE-unsuitable HCC patients who are at risk of liver function deterioration. In addition, patients with ALBI-grade migration in acute or chronic phases had significantly poorer PFS than patients without ALBI-grade migration. Transarterial chemoembolization (TACE) is the standard of care for intermediate stage hepatocellular carcinoma (HCC). We aimed to identify unsuitable cases who were at risk of ALBI-grade migration by TACE. Consecutive 531 BCLC-B HCC patients undergoing TACE were reviewed, and factors associated with ALBI-grade migration were analyzed. There were 129 (24.3%) patients experienced acute ALBI-grade migration after TACE, and 85 (65.9%) out of the 129 patients had chronic ALBI-grade migration. Incidences of acute ALBI-grade migration were 13.9%, 29.0% for patients within or beyond up-to-7 criteria (p < 0.001) and 20.0%, 36.2% for patients within or beyond up-to-11 criteria (p < 0.001), respectively. HBV infection, tumor size plus tumor number criteria were risk factors associated with acute ALBI-grade migration. Bilobar tumor involvement was the risk factor of chronic ALBI-grade migration in patients with acute ALBI-grade migration. Up-to-eleven (p = 0.007) performed better than up-to-seven (p = 0.146) to differentiate risk of dynamic ALBI score changes. Moreover, ALBI-grade migration to grade 3 has adverse effect on survival. In conclusion, tumor burden beyond up-to-eleven was associated with ALBI-grade migration after TACE, indicating that up-to-eleven can select TACE-unsuitable HCC patients who are at risk of liver function deterioration.
引用
收藏
页数:15
相关论文
共 52 条
[1]   Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization [J].
Biolato, Marco ;
Gallusi, Giulia ;
Iavarone, Massimo ;
Cabibbo, Giuseppe ;
Racco, Simona ;
De Santis, Adriano ;
della Corte, Cristina ;
Maida, Marcello ;
Attili, Adolfo Francesco ;
Sangiovanni, Angelo ;
Camma, Calogero ;
La Torre, Giuseppe ;
Gasbarrini, Antonio ;
Grieco, Antonio .
ANNALS OF HEPATOLOGY, 2018, 17 (01) :110-118
[2]   Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions [J].
Bolondi, Luigi ;
Burroughs, Andrew ;
Dufour, Jean-Francois ;
Galle, Peter R. ;
Mazzaferro, Vincenzo ;
Piscaglia, Fabio ;
Raoul, Jean Luc ;
Sangro, Bruno .
SEMINARS IN LIVER DISEASE, 2012, 32 (04) :348-359
[3]   Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma [J].
Boulin, Mathieu ;
Adam, Heloise ;
Guiu, Boris ;
Aho, Ludwig Serge ;
Cercueil, Jean-Pierre ;
Di Martino, Cyrille ;
Fagnoni, Philippe ;
Minello, Anne ;
Jouve, Jean Louis ;
Hillon, Patrick ;
Bedenne, Laurent ;
Lepage, Come .
DIGESTIVE AND LIVER DISEASE, 2014, 46 (04) :358-362
[4]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[5]   Modified CLIP score with the albumin-bilirubin grade retains prognostic value in HBV-related hepatocellular carcinoma patients treated with trans-catheter arterial chemoembolization therapy [J].
Cai, Xiu-Rong ;
Chen, Zhan-Hong ;
Liu, Meng-Meng ;
Lin, Jin-Xiang ;
Zhang, Xiao-Ping ;
Chen, Jie ;
Lin, Qu ;
Ma, Xiao-Kun ;
Wen, Jing-Yun ;
Xie, Si-Dong ;
Wu, Xiang-Yuan ;
Dong, Min .
JOURNAL OF CANCER, 2018, 9 (13) :2380-2388
[6]   Transarterial chemoembolization for unresectable hepatocellular carcinoma:: Meta-analysis of randomized controlled trials [J].
Cammà, C ;
Schepis, F ;
Orlando, A ;
Albanese, M ;
Shahied, L ;
Trevisani, F ;
Andreone, P ;
Craxì, A ;
Cottone, M .
RADIOLOGY, 2002, 224 (01) :47-54
[7]   A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma [J].
Chan, AO ;
Yuen, MF ;
Hui, CK ;
Tso, WK ;
Lai, CL .
CANCER, 2002, 94 (06) :1747-1752
[8]   Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: A retrospective study [J].
Dan, J. -Q. ;
Zhang, Y. -J. ;
Huang, J. -T. ;
Chen, M. -S. ;
Gao, H. -J. ;
Peng, Z-W ;
Xu, L. ;
Lau, W. Y. .
EJSO, 2013, 39 (08) :865-872
[9]  
European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI [10.1016/j.ejca.2011.12.021, 10.1016/j.jhep.2011.12.001]
[10]   The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy [J].
Galle, Peter R. ;
Tovoli, Francesco ;
Foerster, Friedrich ;
Worns, Marcus A. ;
Cucchetti, Alessandro ;
Bolondi, Luigi .
JOURNAL OF HEPATOLOGY, 2017, 67 (01) :173-183